Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Generalized myasthenia gravis

Launch
Not announced
Last updated
120 sources

Economic information and modeling report

Modeling overview

10 evidence topics · 9 sources

Summary

No cost-effectiveness or budget impact model of claseprubart has been published. The ICER evaluation, taking a health system perspective over a 2-year time horizon, estimated $5,210,000 per QALY/evLYG for eculizumab and $2,076,000 per QALY/evLYG for efgartigimod at a placeholder price, and the ratio was never less than $3.8 million per QALY/evLYG for eculizumab or $1.7 million per QALY/evLYG for efgartigimod when model inputs were changed. A Markov model with a lifetime horizon estimated $3,338,000 per QALY gained for eculizumab and $1,987,000 per QALY gained for efgartigimod. A 2026 network meta-analysis using 2026 US costs found efgartigimod IV had the lowest cost per improved outcome among six approved biologics. In Canada, efgartigimod dominated chronic immunoglobulin over a lifetime horizon, and in the United Kingdom thymectomy plus prednisolone dominated prednisolone alone. A study that included 31 articles reported considerable variability in the costs and cost-effectiveness of myasthenia gravis treatments across regions, therapies, and health care settings. The company's market assumption is an average biologic net price of approximately $400,000 per patient per year.

Lifetime U.S. cost-effectiveness of eculizumab and efgartigimod in AChR antibody-positive gMG